Matthew W Foehr Ligand Pharmaceuticals Inc (LGND) insider trading activity

Matthew W Foehr is of LIGAND PHARMACEUTICALS INC. Currently has a direct ownership of 162,187 shares of LGND, which is worth approximately $19.3 Million. The most recent transaction as insider was on Nov 01, 2022, when has been sold 20,304 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 162K

0% 3M change

0% 12M change

Total Value Held $19.3 Million

MATTHEW W FOEHR Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 01 2022	SELL Sale (or disposition) back to the issuer	-	20,304 Reduced 11.13%	162,187 Common Stock
Jun 10 2022	BUY Grant, award, or other acquisition	-	9,137 Added 4.77%	182,491 Common Stock
May 13 2022	BUY Open market or private purchase	$206,900 $82.76 p/Share	2,500 Added 1.42%	173,354 Common Stock
Feb 15 2022	SELL Payment of exercise price or tax liability	$438,569 $123.68 p/Share	3,546 Reduced 2.03%	170,854 Common Stock
Jan 26 2022	SELL Payment of exercise price or tax liability	$582,610 $113.68 p/Share	5,125 Reduced 2.85%	174,400 Common Stock
Jan 26 2022	BUY Grant, award, or other acquisition	-	13,000 Added 6.75%	179,525 Common Stock
Nov 11 2021	SELL Open market or private sale	$1,819,303 $163.02 p/Share	11,160 Reduced 6.28%	166,525 Common Stock
Nov 11 2021	BUY Exercise of conversion of derivative security	$745,296 $61.15 p/Share	12,188 Added 6.42%	177,685 Common Stock
Aug 04 2021	SELL Open market or private sale	$969,483 $109.67 p/Share	8,840 Reduced 5.1%	164,355 Common Stock
Aug 04 2021	BUY Exercise of conversion of derivative security	$537,631 $53.86 p/Share	9,982 Added 5.69%	165,497 Common Stock
May 28 2021	SELL Bona fide gift	-	2,500 Reduced 1.51%	162,600 Common Stock
May 28 2021	BUY Exercise of conversion of derivative security	$98,736 $56.26 p/Share	1,755 Added 1.06%	164,355 Common Stock
Feb 15 2021	SELL Payment of exercise price or tax liability	$534,281 $172.46 p/Share	3,098 Reduced 1.84%	165,100 Common Stock
Feb 04 2021	SELL Open market or private sale	$7,878,582 $176.86 p/Share	44,547 Reduced 20.94%	168,198 Common Stock
Feb 04 2021	BUY Exercise of conversion of derivative security	$2,193,999 $48.17 p/Share	45,547 Added 17.63%	212,745 Common Stock
Feb 03 2021	BUY Grant, award, or other acquisition	-	6,595 Added 3.79%	167,198 Common Stock
Jan 25 2021	SELL Payment of exercise price or tax liability	$518,733 $156.01 p/Share	3,325 Reduced 2.03%	160,603 Common Stock
Jan 25 2021	BUY Grant, award, or other acquisition	-	8,515 Added 4.97%	162,875 Common Stock

Also insider at

VKTX

Viking Therapeutics, Inc. Healthcare

Director

AHPAW

Avista Public Acquisition Corp. II Financial Services

President and CEO

MWF

Matthew W Foehr

Emeryville, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LGND shares.

Notify only if

Value

Insider Trading

Get notified when an Ligand Pharmaceuticals Inc insider buys or sells LGND shares.

Notify only if

Operation

Value

Type

News

Receive news related to LIGAND PHARMACEUTICALS INC

Track Activities on LGND

Account